全球阿兹海默症治疗与诊断市场研究报告——Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

2010-1

摘要

本报告为阿兹海默症的治疗与诊断市场现况，2008年的数据与到2014年的成长率，同市场中所面对的课题，开发中的治疗药物动向与机会，主要企业的数据与专利分析等各种数据交织而成。各条目概述如下。

第1章 绪论

第2章 纲要

第3章 概述

• 市场的定义及构造
  • 什么是阿兹海默症
  • 罹患率及病患数
  • 阿兹海默症的阶段
  • 诊断
• 主要事件
  • 专利期限
  • 新药的上市
• 药价
• 主要市场
• 市场规模与主要企业
  • 治疗
  • 图像诊断
  • SWOT分析

第4章 技术及应用

• 一般的作用机转
  • 胆硷脂酶阻碍剂
  • NMDA阻抗剂
  • 烟酰胺
  • calcineurin酵素
  • GABA调整剂
  • 荷尔蒙
  • 其他
• 映像显示与诊断：物理疗法及应用
  • 核医学
  • CT
  • DEXA
  • MRI
  • 超音波
  • X光
  • 合成图像
  • 阿兹海默症的图像诊断
• 疾病的修正 vs. 症状的治疗
• 药剂的再评价
• 副厂药品

第5章 全球业界构造

• 成长因素
• 阻害成长因素
• 主要的竞争因素
• 国际的观察

第6章 法令与限制环境

• 有効的标的
  • 生物指标不足
• 展开医疗
• 偿还

第7章 相关收购与商业结盟

第8章 输送管道

第9章 动向与课题

• 阿兹海默症的认知度
• 开发中的许多课题及其他

第10章 今后的观察

第11章 专利分析

第12章 企业数据

Abstract

THIS REPORT:

• Focus on the background and the current state of disease-modifying and treatment-of-symptoms therapeutics, and the diagnostics global market segments
• Provide global market data for 2008, estimates for 2009, and forecasts, with compound annual growth rates (CAGRS), through 2014
• Discuss the increasingly difficult challenges that caregivers, families and the healthcare industry face as the number of patients climbs and the frustration with the lack of effective treatments grows
• Review treatments in development and quantify the opportunities in the Alzheimer' s disease market
• Offer detailed company profiles and patent analyses.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC' s goal in conducting this study was to determine the current status of the Alzheimer' s disease treatments and diagnostics and assess the growth potential of this area over a 5-year period from 2009 to 2014. Our key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market and forecast for Alzheimer' s therapeutics and diagnostics, along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

Alzheimer' s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in AD. This study aims to quantify where this market is heading and where the opportunities may lie.

SCOPE OF REPORT

The scope of this report is on the ethical pharmaceutical segment, diagnostics and imaging modalities. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment' s economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this research report. We present an analysis, by each disease area, of the number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2009 through 2014.

INFORMATION SOURCES

BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and diagnostics companies and medical professionals. We also spoke with patients affected by the memory and cognition diseases. In addition, we compiled data from current financial and trade information, and government sources.

Table of Contents

Chapter- 1: INTRODUCTION -- Complimentary 3

• STUDY GOALS AND OBJECTIVES 1
• REASONS FOR DOING THIS STUDY 1
• SCOPE OF REPORT 1
• INTENDED AUDIENCE 2
• METHODOLOGY 2
• INFORMATION SOURCES 2
• ANALYST CREDENTIALS 2
• RELATED BCC REPORTS 2
• BCC ONLINE SERVICES 3
• DISCLAIMER 3

Chapter-2: SUMMARY 2

• SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER' S DISEASE, THROUGH 2014 ($ MILLIONS) 4
• SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER' S DISEASE, 2008-2014 ($ MILLIONS) 4
• FORECAST SUMMARY 5

Chapter-3: OVERVIEW 45

• DEFINITION AND MARKET STRUCTURE 6
• WHAT IS ALZHEIMER' S DISEASE? 6
• TABLE 1 U.S. ALZHEIMER' S PATIENTS, 2000 - 2050 (MILLIONS) 6
• FIGURE 1 U.S. ALZHEIMER' S PATIENTS, 2000 - 2050 (MILLIONS) 7
• Role of the Cholinergic System 7
• Role of Beta-Amyloid Protein 8
• Behavioral Manifestations of AD 9
• INCIDENCE AND PREVALENCE 9
• TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009 - 2050 (MILLIONS) 9
• TABLE 3 PERCENT POPULATION OVER 65, BY REGION (%) 10
• TABLE 4 PEOPLE WITH ALZHEIMER' S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10
• FIGURE 2 PEOPLE WITH ALZHEIMER' S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS) 10
• TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER' S, BY AGE BRACKET 11
• FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER' S, BY AGE BRACKET (%) 11
• TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER' S DISEASE (%) 12
• STAGES OF ALZHEIMER' S DISEASE 12
• Stages of Alzheimer' s ... (Continued) 13
• DIAGNOSIS 14
• TABLE 7 DIAGNOSTIC TESTS 15
• How Accurate are the Screening Tests? 16
• KEY EVENTS 17
• PATENT EXPIRATIONS 17
• NEW PRODUCT LAUNCHES 18
• PRICING 18
• KEY MARKETS 18
• TABLE 8 GLOBAL MARKET FOR ALZHEIMER' S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS) 18
• FIGURE 4 GLOBAL MARKET FOR ALZHEIMER' S DISEASE, BY REGION, 2008-2014 ($ MILLIONS) 19
• MARKET SIZE AND KEY PLAYERS 19
• THERAPEUTICS 20
• TABLE 9 EXISTING TREATMENTS: ALZHEIMER' S DISEASE 20
• TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER' S DISEASE, BY TYPE, 2002 - 2009 ($ MILLIONS) 20
• TABLE 10 (CONTINUED) 21
• TABLE 11 GLOBALMARKET FOR ALZHEIMER' S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN), 2009 ESTIMATED ($ MILLIONS) 21
• TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER' S DISEASE 21
• TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER' S DISEASE, 2008 22
• TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 22
• TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 23
• TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 23
• TABLE 17 GLOBAL TREATMENT OF ALZHEIMER' S DISEASE, THROUGH 2014 ($ MILLIONS) 24
• FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER' S DISEASE, 2007-2014 ($ MILLIONS) 24
• TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2014 ($ MILLIONS) 24
• TABLE 18 (CONTINUED) 25
• FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2008 (%) 25
• Key Players 26
• TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%) 26
• TABLE 20 MARKETED TREATMENTS: ALZHEIMER' S DISEASE 26
• TABLE 20 (CONTINUED) 27
• Drivers 27
• Issues and Challenges 27
• IMAGING AND DIAGNOSTICS 27
• Current Use in Alzheimer' s Disease 27
• Current Use in ... (Continued) 28
• Diagnostic Testing Segments 29
• Imaging 29
• TABLE 21 IMAGING MARKET, 2008 ($ MILLIONS) 30
• FIGURE 7 IMAGING MARKET, 2008 ($ MILLIONS) 30
• Standardization Needed 30
• Diagnostics 31
• Novel Imaging Agents 32
• Opportunities for Biomarkers in AD 33
• TABLE 22 BIOMARKERS FOR ALZHEIMER' S DISEASE 34
• TABLE 22 (CONTINUED) 35
• TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2014 ($ MILLIONS) 36
• FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2008-2014 ($ MILLIONS) 36
• Opportunities for ... (Continued) 37
• Opportunities for ... (Continued) 38
• TABLE 24 U.S. CLINICAL TRIAL MARKET FOR BIOMARKERS BY PHASE - NUMBER OF TRIALS, PATIENTS, BIOMARKER PATIENTS, COST PER TEST, MARKET SIZE, 2008 39
• TABLE 25 CLINICAL TRIAL MARKET FOR BIOMARKERS BY GEOGRAPHICAL REGION, 2008 ($ MILLIONS) 39
• Testing Hypotheses 40
• Diagnostic Tests 40
• Diagnostic Tests (Continued) 41
• Key Players 42
• Agilent Technologies 42
• Bioscan 42
• Capintec Inc. 43
• Digirad Corporation 43
• Gamma Medica-Ideas 43
• GE Healthcare 44
• Hitachi Medical Systems America Inc. 44
• Nymox 44
• OptoSonics Inc. 45
• Philips Healthcare 46
• Positron Corp. 46
• Siemens Healthcare 47
• Spectrum Dynamics Ltd. 47
• Toshiba Medical Systems 48
• UltraSPECT Ltd. 48
• VisEn Medical Inc. 48
• Zecotek Imaging Systems 49
• Drivers 49
• Issues and Challenges 49
• SWOT ANALYSIS 50
• TABLE 26 SWOT ANALYSIS OF EXISTING ALZHEIMER' S DISEASE MARKET AND PLAYERS 50

Chapter-4: TECHNOLOGIES AND APPLICATIONS 22

• COMMON MECHANISMS OF ACTION 51
• CHOLINESTERASE INHIBITORS 52
• TABLE 27 CHOLINESTERASE INHIBITORS 52
• TABLE 28 PRODUCT SIDE EFFECT COMPARISON (%) 53
• FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
• TABLE 29 VACCINES 54
• TABLE 30 ANTI-OXIDANTS 54
• NMDA ANTAGONISTS 54
• TABLE 31 NMDA ANTAGONISTS 55
• NICOTINICS 55
• TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 56
• CALCINEURINS 56
• TABLE 33 CALCINEURINS 56
• GABA MODULATORS 56
• TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 57
• HORMONES 57
• TABLE 35 HORMONES 58
• OTHER THERAPEUTIC MECHANISMS 58
• TABLE 36 OTC TREATMENTS/NATURAL PRODUCTS 59
• IMAGING AND DIAGNOSTICS - MODALITIES AND APPLICATIONS 59
• IMAGING AND DIAGNOSTICS...(CONTINUED) 60
• NUCLEAR MEDICINE 61
• Positron Emission Tomography (PET) 61
• Single Photon Emission Computed Tomography (SPECT) 62
• Gamma Cameras 63
• CT (COMPUTED TOMOGRAPHY) 63
• DEXA 63
• MRI (MAGNETIC RESONANCE IMAGING) 64
• ULTRASOUND 65
• X-RAY 65
• FUSION IMAGING 66
• PET/CT 66
• SPECT/CT 67
• SPECT-CT in Cardiology 67
• SPECT-CT in General Nuclear Medicine 68
• SPECT-CT in Neurology 68
• DIAGNOSTIC IMAGING IN ALZHEIMER' S 69
• DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS 70
• SYMPTOMATIC RELIEF - LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS 71
• OTHER DRUGS TARGETING SYMPTOMATIC RELIEF 71
• DRUG RE-PURPOSING 72
• GENERICS 72

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE 11

• GROWTH DRIVERS 73
• AGING POPULATION 73
• OFF-LABEL USE 74
• UNDERSTANDING OF MECHANISMS 75
• Transcranial Magnetic Stimulation 76
• Genetic Modifications 76
• GROWTH OBSTACLES 77
• UNDERSTANDING OF MECHANISMS 77
• TABLE 37 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 78
• CO-MORBID DISEASE STATES 78
• KEY COMPETITIVE FACTORS 78
• PRODUCT LAUNCH 79
• LIFE CYCLE MANAGEMENT 79
• PAYORS 79
• Payors (Continued) 80
• INTERNATIONAL ASPECTS 81
• TABLE 38 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 82
• INTERNATIONAL ASPECTS (CONTINUED) 83

Chapter-6: LEGISLATION AND REGULATORY ENVIRONMENT 3

• VALIDATED TARGETS 84
• LACK OF BIOMARKERS 84
• TRANSLATIONAL MEDICINE 85
• REIMBURSEMENT 86

Chapter-7: RELATED DEALS AND PARTNERSHIPS 5

• APPROACH 87
• DIAGNOSTICS DEALS 88
• OVERALL ACTIVITY 88
• TABLE 39 RELATED DEALS AND PARTNERSHIPS, 2004 - 2009 89
• TABLE 39 (CONTINUED) 90
• TABLE 39 (CONTINUED) 91

Chapter-8: PIPELINE 8

• PIPELINE 92
• TABLE 40 DEVELOPMENT PIPELINE OF ALZHEIMER' S DRUGS, BY PHASE 93
• TABLE 40 (CONTINUED) 94
• TABLE 40 (CONTINUED) 95
• TABLE 40 (CONTINUED) 96
• TABLE 40 (CONTINUED) 97
• TABLE 40 (CONTINUED) 98
• FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER' S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE 98
• FIGURE 10 (CONTINUED) 99

Chapter-9: TRENDS AND CHALLENGES 4

• AWARENESS OF ALZHEIMER' S 100
• DISEASE PATHWAYS BEING ELUCIDATED 100
• MANY PROGRAMS IN DEVELOPMENT 101
• TABLE 41 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA 101
• MANY PROGRAMS IN DEVELOPMENT (CONTINUED) 102
• TABLE 42 INVESTMENT IN ALZHEIMER' S DISEASE COMPANIES 103

Chapter-10: OUTLOOK 2

• A VARIETY OF APPROACHES IN RESEARCH 104
• MANY PROGRAMS IN DEVELOPMENT 105

Chapter-11: PATENT ANALYSIS 26

• TABLE 43 KEY PATENT EXPIRY - ALZHEIMER' S THERAPEUTICS, BY CATEGORY 106
• TABLE 44 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER' S THERAPEUTICS AND TECHNOLOGIES 107
• TABLE 45 PATENT APPLICATIONS (U.S.) 107
• TABLE 45 (CONTINUED) 108
• TABLE 45 (CONTINUED) 109
• TABLE 45 (CONTINUED) 110
• TABLE 45 (CONTINUED) 111
• TABLE 45 (CONTINUED) 112
• TABLE 45 (CONTINUED) 113
• TABLE 45 (CONTINUED) 114
• TABLE 45 (CONTINUED) 115
• TABLE 45 (CONTINUED) 116
• TABLE 45 (CONTINUED) 117
• TABLE 45 (CONTINUED) 118
• TABLE 45 (CONTINUED) 119
• TABLE 45 (CONTINUED) 120
• TABLE 46 ISSUED PATENTS (U.S.) 120
• TABLE 46 (CONTINUED) 121
• TABLE 46 (CONTINUED) 122
• TABLE 46 (CONTINUED) 123
• TABLE 46 (CONTINUED) 124
• TABLE 46 (CONTINUED) 125
• TABLE 46 (CONTINUED) 126
• TABLE 46 (CONTINUED) 127
• TABLE 46 (CONTINUED) 128
• TABLE 46 (CONTINUED) 129
• TABLE 46 (CONTINUED) 130
• TABLE 46 (CONTINUED) 131

Chapter-12: COMPANY PROFILES 46

• ABLYNX 132
• ACCERA, INC. 132
• ACUMEN PHARMACEUTICALS 133
• AFFIRIS AG 133
• AFFITECH AS 134
• ALLON THERAPEUTICS (FKA NEURODISCOVERY) 134
• ALZHYME PTY 135
• ASTELLAS 135
• ASTRAZENECA 136
• ATHENA DIAGNOSTICS (THERMO FISHER) 136
• AVERA PHARMACEUTICALS 137
• BAXTER HEALTHCARE 137
• BAYER SCHERING PHARMA 138
• BELLUS HEALTH 138
• BIOFUTURA 139
• BIOMERIEUX 139
• BIOVAIL 140
• BOEHRINGER INGELHEIM 140
• BRACCO 140
• BRAINCELLS, INC. 140
• BRISTOL MYERS SQUIBB 141
• CELLZOME 141
• CEREGENE 142
• COGNITION PHARMACEUTICALS LLC 142
• COGNITION THERAPEUTICS 142
• COLUCID PHARMACEUTICALS 143
• COMENTIS 143
• CORTEX PHARMACEUTICALS 144
• C2N DIAGNOSTICS 144
• CYTOS BIOTECHNOLOGY 145
• DAIICHI SANKYO 145
• DEBIOPHARM 146
• DURECT 146
• EISAI 146
• ELAN 147
• ELI LILLY 147
• ENVIVO PHARMACEUTICALS 148
• ESTEVE 148
• EVOTEC 149
• EXONHIT THERAPEUTICS 149
• FOREST LABORATORIES 150
• GALANTOS PHARMA 150
• GALENEA 151
• GE HEALTHCARE 151
• GLAXOSMITH KLINE 152
• HELICON THERAPEUTICS 152
• INTELLECT NEUROSCIENCES 153
• INTRA-CELLULAR THERAPIES 153
• INVERNESS MEDICAL INNOVATIONS 154
• IPSEN 154
• JOHNSON & JOHNSON 155
• KEYNEUROTEK 155
• LEXICON PHARMACEUTICALS 155
• LINK MEDICINE 156
• LUNDBECK 156
• MEDIVATION 157
• MEMORY PHARMACEUTICALS 157
• MERCK 158
• MERCKSERONO 158
• MERZ PHARMA 158
• MITHRIDION 159
• MITSUBISHI TANABE 159
• MORPHOSYS 160
• MP BIOMEDICALS 161
• NEUREN PHARMACEUTICALS 161
• NEUROPTIX 162
• NEUROSEARCH 163
• NEURO-HITECH 163
• NEWRON PHARMACEUTICALS 163
• NOSCIRA SA 164
• NOVARTIS 165
• NYMOX 165
• OLIGOMERIX 166
• ORTHO-MCNEIL NEUROLOGICS 166
• PFIZER 166
• POWER3 MEDICAL PRODUCTS 167
• PRANA BIOTECHNOLOGY 167
• PROTEOTECH INC. 168
• PSYCHOGENICS 168
• ROCHE 168
• SAMARITAN PHARMACEUTICALS 169
• SANOFI-AVENTIS 170
• SATORI PHARMACEUTICALS 170
• SATORIS 170
• SCIELE PHARMA 171
• SIEMENS MEDICAL SOLUTIONS 171
• SOLVAY 172
• SUVEN LIFE SCIENCE 172
• TAKEDA 173
• TARGACEPT 173
• TAURX THERAPEUTICS 173
• TAUTATIS 174
• TEIKOKU 175
• TEVA PHARMACEUTICALS 175
• TRANSTECH PHARMA 175
• VOYAGER PHARMACEUTICAL / DURAMED 176
• WATSON PHARMACEUTICALS 176
• WYETH/PFIZER 177